Compounds > glycerol 1-stearate
Page last updated: 2024-09-22

glycerol 1-stearate

Description

glycerol 1-stearate: isolated from the young fronds of the bracken fern Pteridium aquilinum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

rac-1-monostearoylglycerol : A rac-1-monoacylglycerol composed of equal amounts of 3-stearoyl-sn-glycerol and 1-stearoyl-sn-glycerol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

1-monostearoylglycerol : A 1-monoglyceride that has stearoyl as the acyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID24699
CHEMBL ID255696
CHEBI ID75555
CHEBI ID75557
SCHEMBL ID4488
MeSH IDM0522764

Synonyms (231)

Synonym
83138-62-9
c21h42o4
.alpha.-monostearin
glycerol .alpha.-monostearate
123-94-4
stearic acid 1-monoglyceride
stearic acid .alpha.-monoglyceride
glycerol 1-stearate
nsc-3875
monostearin (l)
octadecanoic acid,3-dihydroxypropyl ester
tegin
3-stearoyloxy-1,2-propanediol
aldo 75
1-monostearoylglycerol
tegin 515
aldo 33
octadecanoic acid, 2,3-dihydroxypropyl ester
arlacel 165
nsc3875 ,
sandin eu
emerest 2407
glycerin 1-monostearate
glycerin 1-stearate
stearin, 1-mono-
tegin 55g
1-glyceryl stearate
glyceryl 1-monostearate
glycerol 1-monostearate
aldo mslg
1-monostearin
aldo msd
alpha-monostearin
inchi=1/c21h42o4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(24)25-19-20(23)18-22/h20,22-23h,2-19h2,1h
glyceryl stearate
kessco 40
ogeen mav
tegin 503
cerasynt sd
glyceryl monooctadecanoate
stearic monoglyceride
cerasynt wm
drewmulse tp
starfol gms 450
admul
arlacel 169
emcol ca
estol 603
myvaplex 600
monoglyceryl stearate
grocor 5500
starfol gms 900
protachem gms
imwitor 900k
aldo hms
ogeen grb
ai3-00966
stearoylglycerol
sedetine
cerasynt 1000-d
monostearate (glyceride)
lipo gms 600
glycerin monostearate
cefatin
atmos 150
atmul 84
orbon
einecs 250-705-4
aldo-72
emcol msk
aldo-28
hodag gms
emerest 2401
glyceryl monostearate
atmul 67
cyclochem gms
octadecanoic acid, monoester with 1,2,3-propanetriol
arlacel 161
imwitor 191
stearic acid, monoester with glycerol
starfol gms 600
lipo gms 450
ogeen m
ogeen 515
unimate gms
monostearin
emul p.7
dermagine
usaf ke-7
monelgin
citomulgan m
aldo ms
atmul 124
drumulse aa
witconol ms
lipo gms 410
witconol mst
celinhol - a
drewmulse v
cerasynt s
glycerol monostearate
armostat 801
grocor 6000
1,2,3-propanetriol monooctadecanoate
cerasynt se
2,3-dihydroxypropyl octadecanoate
1-octadecanoyl-rac-glycerol
mg(18:0/0:0/0:0)[rac]
LMGL01010003
1-stearoyl-rac-glycerol, >=99%
31566-31-1
glyceryl monostearate (jp17/nf)
D01947
NCGC00164529-01
glycerol alpha-monostearate
einecs 204-664-4
fema no. 2527
(1)-2,3-dihydroxypropyl stearate
glycerol stearate, pure
einecs 245-121-1
nsc 3875
stearic acid alpha-monoglyceride
11099-07-3
octadecanoic acid, ester with 1,2,3-propanetriol
2,3-dihydroxypropyl stearate
S-7950
1-stearoyl-rac-glycerol
cerasynt-sd
glycerol stearate
cutina gms
glycerides, c16-18 mono-
lonzest gms
glyceryl monopalmitostearate
CHEMBL255696
stearin, mono-
monoglycerides, c16-18
cithrol gms 0400
nikkol mgs-a
cremophor gmsk
imwitor 491
chebi:75555 ,
glyceroli monostearas
sorbon mg-100
22610-63-5
1-monostearoyl-rac-glycerol
1-monooctadecanoylglycerol
1-o-octadecanoyl-2n-glycerol
G0085
NCGC00164529-03
NCGC00164529-02
einecs 238-880-5
unii-230ou9xxe4
ec 293-208-8
230ou9xxe4 ,
einecs 293-208-8
dsstox_cid_9160
tox21_301104
NCGC00255004-01
cas-11099-07-3
dsstox_rid_78757
dsstox_gsid_29304
cas-123-94-4
dtxcid909160
dtxsid7029160 ,
NCGC00260122-01
tox21_112160
tox21_202573
rac-glyceryl monostearate
(+-)-2,3-dihydroxypropyl octadecanoate
(+-)-glyceryl monostearate
rac-2,3-dihydroxypropyl octadecanoate
rac-1-monostearoylglycerol
(+-)-1-stearoylglycerol
glycerol 1-octadecanoate
(+-)-1-octadecanoylglycerol
rac-octadecanoylglycerol
CHEBI:75557
1-octadecanoylglycerol
(+-)-1-monostearoylglycerol
glyceryl stearates
abracol s.l.g.
ec 250-705-4
eastman 600
glyceryl monostearate [jan:nf]
FT-0674656
258491e1rz ,
unii-258491e1rz
FT-0626740
FT-0626748
AKOS015901589
rac-glycerol 1-stearate
1-monooctadecanoyl-rac-glycerol
85666-92-8
glyceryl 1-stearate
glyceryl monostearate 40-50
(+/-)-2,3-dihydroxypropyl octadecanoate
glyceryl 1-octadecanoate
SCHEMBL4488
tox21_112160_1
NCGC00164529-04
1-o-stearoylglycerol
octadecanoic acid, 2.3-dihydroxypropyl ester
glycerol .alpha.-sterate
1,2,3-propanetriol 1-octadecanoyl ester
2,3-dihydroxypropyl stearate #
Q-201168
W-110285
(+/-)-2,3-dihydroxypropyl octadecanoate; 1-glyceryl stearate; 1-monooctadecanoylglycerol; 1-monostearin
mfcd00036186
glycerol monostearate, purified
SR-01000944874-1
sr-01000944874
mag 18:0
A903419
Q5572563
glycerol monostearate (gms)
342394-34-7
DB11250
geleol mono and diglycerides
1-stearoyl-rac-glycerol (90per cent)
A890632
BS-50505
1-stearoyl-rac-glycerol (90%)
()-2,3-dihydroxypropyl octadecanoate; 1-glyceryl stearate; 1-monooctadecanoylglycerol; 1-monostearin
glycerol monostearate 40-55
octadecanoic acid, 2,3-dihydroxypropyl ester, (a+/-)-
DTXSID7027968 ,
F71433
celinhol-a
glyceryl stearate (ii)
glyceryl monostearate (ii)

Roles (2)

RoleDescription
algal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in algae including unicellular organisms like chlorella and diatoms to multicellular organisms like giant kelps and brown algae.
Caenorhabditis elegans metaboliteA nematode metabolite produced by Caenorhabditis elegans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
1-acylglycerol 18:0A 1-monoglyceride in which the acyl group contains 18 carbons and is fully saturated.
rac-1-monoacylglycerolA racemate that is composed of equal amounts of 1-acyl-sn-glycerol and 3-acyl-sn-glycerol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
USP1 protein, partialHomo sapiens (human)Potency4.46680.031637.5844354.8130AID504865
AR proteinHomo sapiens (human)Potency12.61720.000221.22318,912.5098AID1259243; AID743036; AID743054
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency0.67500.001022.650876.6163AID1224838
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency13.44810.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency9.53530.003041.611522,387.1992AID1159552
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency2.68740.001530.607315,848.9004AID1224841
estrogen nuclear receptor alphaHomo sapiens (human)Potency3.09820.000229.305416,493.5996AID743075
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency15.244219.739145.978464.9432AID1159509
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency31.62280.010323.856763.0957AID2662
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency31.62280.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID331221Inhibition of COX2 at 50 uM2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Monoglycerides from the brown alga Sargassum sagamianum: Isolation, synthesis, and biological activity.
AID331222Inhibition of sPLA2-2A at 10 uM by coupled enzyme assay2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Monoglycerides from the brown alga Sargassum sagamianum: Isolation, synthesis, and biological activity.
AID332270Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay2002Journal of natural products, Feb, Volume: 65, Issue:2
Lignanamides and nonalkaloidal components of Hyoscyamus niger seeds.
AID681134TP_TRANSPORTER: Daunomycin accumulation in Caco-2 cells2004British journal of pharmacology, Oct, Volume: 143, Issue:3
Inhibitory effect of a bitter melon extract on the P-glycoprotein activity in intestinal Caco-2 cells.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (177)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (2.82)18.7374
1990's4 (2.26)18.2507
2000's56 (31.64)29.6817
2010's89 (50.28)24.3611
2020's23 (12.99)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.55%)6.00%
Case Studies4 (2.20%)4.05%
Observational0 (0.00%)0.25%
Other177 (97.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
feruloyltyramine[no description available]medium10tyraminesmetabolite
monolinolein[no description available]medium201-acylglycerol 18:2;
rac-1-monoacylglycerol		antiviral agent;
human metabolite;
plant metabolite
cannabisin g[no description available]medium10
glycerol[no description available]medium110alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent
palmitic acid[no description available]medium10long-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor;
plant metabolite
tripalmitin[no description available]medium30triglyceride
monolaurin[no description available]medium101-monoglyceride;
dodecanoate ester;
rac-1-monoacylglycerol
rac-glycerol 1-monodecanoate[no description available]medium10rac-1-monoacylglycerol
2-palmitoylglycerol[no description available]medium102-acylglycerol 16:0algal metabolite
monooctanoin[no description available]medium101-monoglyceride;
octanoate ester;
rac-1-monoacylglycerol
1-monooleoyl-rac-glycerol[no description available]medium801-acylglycerol 18:1;
monooleoylglycerol		plant metabolite
stearates[no description available]medium80
albuterol[no description available]medium10phenols;
phenylethanolamines;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
environmental contaminant;
xenobiotic
stearic acid[no description available]medium150long-chain fatty acid;
saturated fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
human metabolite;
plant metabolite
flufenamic acid[no description available]medium10aromatic amino acid;
organofluorine compound		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
5-hydroxy-2-pyrrolidone[no description available]medium10
shikimic acid[no description available]medium10alpha,beta-unsaturated monocarboxylic acid;
cyclohexenecarboxylic acid;
hydroxy monocarboxylic acid		Escherichia coli metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
benzoic acid[no description available]medium10benzoic acidsalgal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite
sesquiterpenes[no description available]medium20
cytellin[no description available]medium10
fluconazole[no description available]medium10conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
chitosan[no description available]medium30
glycolipids[no description available]medium10
tristearin[no description available]medium60triacylglycerol 54:0Caenorhabditis elegans metabolite;
plant metabolite
resveratrol[no description available]medium20resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
1,2-dipalmitoylphosphatidylcholine[no description available]medium10
tamoxifen[no description available]medium20stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
carbitol[no description available]medium10diether;
glycol ether;
hydroxypolyether;
primary alcohol		protic solvent
efavirenz[no description available]medium10acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
docetaxel anhydrous[no description available]medium20secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
mupirocin[no description available]medium10alpha,beta-unsaturated carboxylic ester;
epoxide;
monocarboxylic acid;
oxanes;
secondary alcohol;
triol		antibacterial drug;
bacterial metabolite;
protein synthesis inhibitor
astaxanthine[no description available]medium10carotenol;
carotenone		animal metabolite;
anticoagulant;
antioxidant;
food colouring;
plant metabolite
ethyl cellulose[no description available]medium60glycoside
glyceryl behenate[no description available]medium701-monoglyceride;
fatty acid ester		antineoplastic agent;
plant metabolite
eperisone[no description available]medium10aromatic ketone;
piperidines
cellulose[no description available]medium110glycoside
hydrogen[no description available]medium40elemental hydrogen;
elemental molecule;
gas molecular entity		antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite
lactose[no description available]medium40lactose
methylcellulose[no description available]medium10
precirol[no description available]medium70
meclizine[no description available]medium10diarylmethane
olanzapine[no description available]medium20benzodiazepine;
N-arylpiperazine;
N-methylpiperazine		antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor
sorbitan monostearate[no description available]medium20
galactose[no description available]medium30
aluminum magnesium silicate[no description available]medium10
ibuprofen[no description available]medium20monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
tricalcium phosphate[no description available]medium20calcium phosphate
praziquantel[no description available]medium20isoquinolines
eudragit-e[no description available]medium30
citral[no description available]medium10enal;
monoterpenoid;
polyprenal		plant metabolite;
volatile oil component
sorbitan monooleate[no description available]medium10fatty acid ester
lipoamide[no description available]medium10dithiolanes;
monocarboxylic acid amide		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
1-anilino-8-naphthalenesulfonate[no description available]medium30aminonaphthalene;
naphthalenesulfonic acid		fluorescent probe
curcumin[no description available]medium30aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
methacycline[no description available]medium101,2-diglyceride
atenolol[no description available]medium10ethanolamines;
monocarboxylic acid amide;
propanolamine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic
oxiconazole[no description available]medium10conazole antifungal drug;
dichlorobenzene;
imidazole antifungal drug;
imidazoles;
oxime O-ether		antiinfective agent
oleic acid[no description available]medium80octadec-9-enoic acidantioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent
gingerol[no description available]medium10beta-hydroxy ketone;
guaiacols		antineoplastic agent;
plant metabolite
sucrose[no description available]medium10glycosyl glycosidealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent
calpain[no description available]medium10
beta carotene[no description available]medium10carotenoid beta-end derivative;
cyclic carotene		antioxidant;
biological pigment;
cofactor;
ferroptosis inhibitor;
human metabolite;
mouse metabolite;
plant metabolite;
provitamin A
lutein[no description available]medium10carotenolfood colouring;
plant metabolite
dronedarone[no description available]medium101-benzofurans;
aromatic ether;
aromatic ketone;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
environmental contaminant;
xenobiotic
d-alpha tocopherol[no description available]medium10alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite
ethyl citrate[no description available]medium10carbonyl compound
eudragit rs[no description available]medium20
amphotericin b[no description available]medium10antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
propylene glycol[no description available]medium20glycol;
propane-1,2-diols		allergen;
human xenobiotic metabolite;
mouse metabolite;
protic solvent
dalteparin[no description available]medium10
gliclazide[no description available]medium10N-sulfonylureahypoglycemic agent;
insulin secretagogue;
radical scavenger
nifedipine[no description available]medium10C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
theophylline[no description available]medium70dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent
trehalose[no description available]medium20trehaloseEscherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
technetium[no description available]medium10manganese group element atom
duloxetine hydrochloride[no description available]medium10duloxetine hydrochlorideantidepressant
thiophenes[no description available]medium10mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
carvedilol[no description available]medium20carbazoles;
secondary alcohol;
secondary amino compound		alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent
ondansetron[no description available]medium10carbazoles
fluorouracil[no description available]medium20nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
trimyristin[no description available]medium20tetradecanoate ester;
triglyceride
acetaminophen[no description available]medium90acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
bixin[no description available]medium10
zanamivir[no description available]medium20guanidinesantiviral agent;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
metronidazole[no description available]medium20C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
glucuronic acid[no description available]medium10D-glucuronic acidalgal metabolite
methanol[no description available]medium10alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound		amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite
naproxen[no description available]medium10methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
mannans[no description available]medium20
2-pyrrolidone[no description available]medium10pyrrolidin-2-onesmetabolite;
polar solvent
shellac[no description available]medium10
dimethyl sulfoxide[no description available]medium10sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
n-methylpyrrolidone[no description available]medium10lactam;
N-alkylpyrrolidine;
pyrrolidin-2-ones		polar aprotic solvent
paclitaxel[no description available]medium40taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
phosphatidylcholines[no description available]medium301,2-diacyl-sn-glycero-3-phosphocholine
isradipine[no description available]medium10benzoxadiazole;
dihydropyridine;
isopropyl ester;
methyl ester
flunarizine[no description available]medium10diarylmethane
candesartan cilexetil[no description available]medium10biphenyls
stearylamine[no description available]medium30primary aliphatic aminefilm-forming compound
fluorescein-5-isothiocyanate[no description available]medium20fluorescein isothiocyanate
adefovir dipivoxil[no description available]medium106-aminopurines;
carbonate ester;
ether;
organic phosphonate		antiviral drug;
DNA synthesis inhibitor;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent;
prodrug
adenine[no description available]medium106-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
organophosphonates[no description available]medium10divalent inorganic anion;
phosphite ion
n-vinyl-2-pyrrolidinone[no description available]medium20pyrrolidin-2-ones
folic acid[no description available]medium20folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient
rhodamine 123[no description available]medium20organic cation;
xanthene dye		fluorochrome
cetostearyl alcohol[no description available]medium10
quercetin[no description available]medium207-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
miconazole[no description available]medium10dichlorobenzene;
ether;
imidazoles
oleyl alcohol[no description available]medium10fatty alcohol 18:1;
long-chain primary fatty alcohol		metabolite;
nonionic surfactant
cimetidine[no description available]medium10aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
titanium[no description available]medium20titanium group element atom
titanium dioxide[no description available]medium20titanium oxidesfood colouring
caffeine[no description available]medium10purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
tretinoin[no description available]medium10retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule
deoxycholic acid[no description available]medium20bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human blood serum metabolite
mannitol[no description available]medium20mannitolallergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent
solutol hs 15[no description available]medium10aliphatic alcohol
apomorphine[no description available]medium10aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
oxybenzone[no description available]medium10hydroxybenzophenone;
monomethoxybenzene		dermatologic drug;
environmental contaminant;
protective agent;
ultraviolet filter;
xenobiotic
stilbenes[no description available]medium10stilbene
chloramphenicol[no description available]medium10C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
tributyl citrate[no description available]medium10carbonyl compound
tetrandrine[no description available]medium10bisbenzylisoquinoline alkaloid;
isoquinolines
delphinidin[no description available]medium10anthocyanidin chloride
cetyl palmitate[no description available]medium20hexadecanoate estermetabolite
hydrochloric acid[no description available]medium10chlorine molecular entity;
gas molecular entity;
hydrogen halide;
mononuclear parent hydride		mouse metabolite
methylene chloride[no description available]medium10chloromethanes;
volatile organic compound		carcinogenic agent;
polar aprotic solvent;
refrigerant
ciprofloxacin[no description available]medium20aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
pectins[no description available]medium20D-galactopyranuronic acid
thiazolyl blue[no description available]medium10organic bromide saltcolorimetric reagent;
dye
lactobionic acid[no description available]medium10disaccharideantioxidant
galactose[no description available]medium10D-galactose;
galactopyranose		Escherichia coli metabolite;
mouse metabolite
acetone[no description available]medium10ketone body;
methyl ketone;
propanones;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
human metabolite;
polar aprotic solvent
thiazoles[no description available]medium101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
lactic acid[no description available]medium102-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
piperidines[no description available]medium10
repaglinide[no description available]medium10piperidines
carbamates[no description available]medium10amino-acid anion
isotretinoin[no description available]medium10retinoic acidantineoplastic agent;
keratolytic drug;
teratogenic agent
cp 102[no description available]medium10
bromhexine[no description available]medium10organobromine compound;
substituted aniline;
tertiary amino compound		mucolytic
calcium phosphate, dibasic, dihydrate[no description available]medium10calcium salt;
hydrate
ethyl ferulate[no description available]medium10
clobetasol[no description available]medium2011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
fluorinated steroid;
glucocorticoid;
tertiary alpha-hydroxy ketone		anti-inflammatory drug;
SMO receptor agonist
glycine[no description available]medium10alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
clarithromycin[no description available]medium10macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
cholesteryl oleate[no description available]medium10CE(18:1);
cholesteryl octadec-9-enoate		mouse metabolite
triolein[no description available]medium10triglycerideCaenorhabditis elegans metabolite;
plant metabolite
squalene[no description available]medium10triterpenehuman metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
linoleic acid[no description available]medium10octadecadienoic acid;
omega-6 fatty acid		algal metabolite;
Daphnia galeata metabolite;
plant metabolite
vancomycin[no description available]medium10glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
tricaprylin[no description available]medium10octanoate ester;
triglyceride		anticonvulsant;
plant metabolite
piroxicam[no description available]medium10benzothiazine;
monocarboxylic acid amide;
pyridines		analgesic;
antirheumatic drug;
cyclooxygenase 1 inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
caprylates[no description available]medium10fatty acid anion 8:0;
straight-chain saturated fatty acid anion		human metabolite;
Saccharomyces cerevisiae metabolite
behenic acid[no description available]medium10long-chain fatty acid;
straight-chain saturated fatty acid		plant metabolite
myristic acid[no description available]medium10long-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite
beta-elemene[no description available]medium10beta-elemeneantineoplastic agent
vinpocetine[no description available]medium10alkaloidgeroprotector
sitagliptin phosphate[no description available]medium10
pyrazines[no description available]medium10diazine;
pyrazines		Daphnia magna metabolite
triazoles[no description available]medium101,2,3-triazole
nitrendipine[no description available]medium10C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester		antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent
isosilybin[no description available]medium10
silychristin[no description available]medium101-benzofurans;
aromatic ether;
flavonolignan;
polyphenol;
secondary alpha-hydroxy ketone		lipoxygenase inhibitor;
metabolite;
prostaglandin antagonist;
radical scavenger
taxifolin[no description available]medium10taxifolinmetabolite
silybin[no description available]medium10
silidianin[no description available]medium10
3-hydroxyflavone[no description available]medium10flavonols;
monohydroxyflavone
guaifenesin[no description available]medium10methoxybenzenes
nimodipine[no description available]medium102-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester		antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent
cyclosporine[no description available]medium10
stearyl alcohol[no description available]medium10long-chain primary fatty alcohol;
octadecanol		algal metabolite;
human metabolite;
plant metabolite
brij-58[no description available]medium10
diltiazem[no description available]medium105-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetateantihypertensive agent;
calcium channel blocker;
vasodilator agent
cefazolin[no description available]medium10beta-lactam antibiotic allergen;
cephalosporin;
tetrazoles;
thiadiazoles		antibacterial drug
diclofenac[no description available]medium10amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
betadex[no description available]medium10cyclodextrin
isostearyl alcohol[no description available]medium10long-chain primary fatty alcohol
2-keto-4-methylvalerate[no description available]low002-oxo monocarboxylic acid;
branched-chain keto acid		algal metabolite;
human metabolite
4-hydroxybenzoic acid[no description available]low00monohydroxybenzoic acidalgal metabolite;
plant metabolite
salicylic acid[no description available]low00monohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite
phloroglucinol[no description available]low00benzenetriol;
phenolic donor		algal metabolite
n(1)-methylnicotinamide[no description available]low00pyridinium ionalgal metabolite;
anti-inflammatory agent;
human urinary metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
3-phosphoglycerate[no description available]low00monophosphoglyceric acid;
tetronic acid derivative		algal metabolite;
fundamental metabolite
alpha-glycerophosphoric acid[no description available]low00glycerol monophosphatealgal metabolite;
human metabolite
hydroxylamine[no description available]low00hydroxylaminesalgal metabolite;
bacterial xenobiotic metabolite;
EC 1.1.3.13 (alcohol oxidase) inhibitor;
EC 4.2.1.22 (cystathionine beta-synthase) inhibitor;
EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor;
nitric oxide donor;
nucleophilic reagent
racemethionine[no description available]low00alpha-amino acid;
amino acid zwitterion;
sulfur-containing amino acid		algal metabolite;
Daphnia magna metabolite;
Escherichia coli metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
oxalic acid[no description available]low00alpha,omega-dicarboxylic acidalgal metabolite;
human metabolite;
plant metabolite
phosphoric acid[no description available]low00phosphoric acidsalgal metabolite;
fertilizer;
human metabolite;
NMR chemical shift reference compound;
solvent
phosphorylethanolamine[no description available]low00phosphoethanolamine;
primary amino compound		algal metabolite;
human metabolite;
mouse metabolite
dimethyl sulfide[no description available]low00aliphatic sulfidealgal metabolite;
bacterial xenobiotic metabolite;
EC 3.5.1.4 (amidase) inhibitor;
Escherichia coli metabolite;
marine metabolite
tramiprosate[no description available]low00amino sulfonic acid;
zwitterion		algal metabolite;
anti-inflammatory agent;
anticonvulsant;
GABA agonist;
nootropic agent
acetohydroxamic acid[no description available]low00acetohydroxamic acids;
carbohydroximic acid		algal metabolite;
EC 3.5.1.5 (urease) inhibitor
cetyl alcohol[no description available]low00hexadecanol;
long-chain primary fatty alcohol		algal metabolite;
flavouring agent;
human metabolite;
plant metabolite
decanoic acid[no description available]low00medium-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
anti-inflammatory agent;
antibacterial agent;
human metabolite;
plant metabolite;
volatile oil component
methylene bromide[no description available]low00bromohydrocarbon;
bromomethanes		algal metabolite;
marine metabolite
harmalol[no description available]low00harmala alkaloidalgal metabolite;
EC 1.4.3.4 (monoamine oxidase) inhibitor
lauric acid[no description available]low00medium-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
antibacterial agent;
plant metabolite
isonicotinic acid[no description available]low00pyridinemonocarboxylic acidalgal metabolite;
human metabolite
dipropylenetriame[no description available]low00polyazaalkanealgal metabolite;
plant metabolite
serine[no description available]low00L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
lysine[no description available]low00aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
leucine[no description available]low00amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
phenylalanine[no description available]low00amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
ornithine[no description available]low00non-proteinogenic L-alpha-amino acid;
ornithine		algal metabolite;
hepatoprotective agent;
mouse metabolite
histidine[no description available]low00amino acid zwitterion;
histidine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
valine[no description available]low00L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
threonine[no description available]low00amino acid zwitterion;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
threonine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
isoleucine[no description available]low00aspartate family amino acid;
isoleucine;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
methyl bromide[no description available]low00bromohydrocarbon;
bromomethanes;
methyl halides		algal metabolite;
fumigant insecticide;
marine metabolite
3-mercaptopropionic acid[no description available]low00mercaptopropanoic acidalgal metabolite
pyrrolidonecarboxylic acid[no description available]low005-oxoproline;
L-proline derivative;
non-proteinogenic L-alpha-amino acid		algal metabolite
ethylene dibromide[no description available]low00bromoalkane;
bromohydrocarbon		algal metabolite;
carcinogenic agent;
fumigant;
marine metabolite;
mouse metabolite;
mutagen
pelargonic acid[no description available]low00medium-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
antifeedant;
Daphnia magna metabolite;
plant metabolite
margaric acid[no description available]low00long-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
mammalian metabolite
2-hydroxybutyric acid[no description available]low002-hydroxy monocarboxylic acid;
hydroxybutyric acid		algal metabolite;
human metabolite
homoserine[no description available]low00amino acid zwitterion;
homoserine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
Saccharomyces cerevisiae metabolite
methylphosphate[no description available]low00monoalkyl phosphate;
one-carbon compound		algal metabolite;
epitope;
phosphoantigen
pentadecanoic acid[no description available]low00long-chain fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
food component;
human blood serum metabolite;
plant metabolite
butyl stearate[no description available]low00fatty acid esteralgal metabolite
beta-aminoglutaric acid[no description available]low00dicarboxylic acidalgal metabolite;
marine metabolite
gamma-tocopherol[no description available]low00tocopherol;
vitamin E		algal metabolite;
food antioxidant;
plant metabolite
6-bromo-3-(bromomethyl)-7-methyl-2,3,7-trichloro-1-octene[no description available]low00monoterpenoid;
organobromine compound;
organochlorine compound		algal metabolite;
antineoplastic agent;
marine metabolite
proline[no description available]low00amino acid zwitterion;
glutamine family amino acid;
L-alpha-amino acid;
proline;
proteinogenic amino acid		algal metabolite;
compatible osmolytes;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
altritol[no description available]low00hexitolalgal metabolite;
marine metabolite
5'-methylthioadenosine[no description available]low00thioadenosinealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
d-2-hydroxyglutarate[no description available]low002-hydroxyglutaric acidalgal metabolite
maleic acid[no description available]low00butenedioic acidalgal metabolite;
mouse metabolite;
plant metabolite
docosahexaenoate[no description available]low00docosahexaenoic acid;
omega-3 fatty acid		algal metabolite;
antineoplastic agent;
Daphnia tenebrosa metabolite;
human metabolite;
mouse metabolite;
nutraceutical
palmitoleic acid[no description available]low00hexadec-9-enoic acidalgal metabolite;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
human blood serum metabolite
sodium benzoate[no description available]low00organic sodium saltalgal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite
trans-phytol[no description available]low00diterpenoid;
long-chain primary fatty alcohol		algal metabolite;
plant metabolite;
schistosomicide drug
brassicasterol[no description available]low003beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
ergostanoid;
phytosterols		algal metabolite;
animal metabolite;
biomarker;
EC 1.3.1.72 (Delta(24)-sterol reductase) inhibitor;
human metabolite;
marine metabolite;
plant metabolite;
sterol biosynthesis inhibitor
domoic acid[no description available]low00L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid;
tricarboxylic acid		algal metabolite;
hapten;
marine metabolite;
neuromuscular agent;
neurotoxin
docosapentaenoic acid[no description available]low00docosapentaenoic acid;
omega-3 fatty acid		algal metabolite;
human metabolite
adonixanthin[no description available]low00carotenone;
cyclic ketone;
secondary alcohol		algal metabolite;
animal metabolite;
antineoplastic agent;
bacterial metabolite;
marine metabolite;
plant metabolite
debromoaplysiatoxin[no description available]low00aplysiatoxins;
cyclic hemiketal;
ether;
organic heterotricyclic compound;
phenols;
secondary alcohol;
spiroketal		algal metabolite;
carcinogenic agent;
cyanotoxin;
marine metabolite;
protein kinase C agonist
aplysiatoxin[no description available]low00aplysiatoxins;
bromophenol;
cyclic hemiketal;
ether;
organic heterotricyclic compound;
secondary alcohol;
spiroketal		algal metabolite;
carcinogenic agent;
cyanotoxin;
marine metabolite;
protein kinase C agonist
guanine[no description available]low002-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
2-aminoadipic acid[no description available]low00amino dicarboxylic acid;
dicarboxylic fatty acid;
non-proteinogenic alpha-amino acid		Caenorhabditis elegans metabolite;
mammalian metabolite
ascr#3[no description available]low00(omega-1)-hydroxy fatty acid ascaroside;
alpha,beta-unsaturated monocarboxylic acid		Caenorhabditis elegans metabolite;
pheromone
delta7-dafachronic acid[no description available]low00Delta(7)-dafachronic acidCaenorhabditis elegans metabolite
ascr#5[no description available]low00monocarboxylic acid;
omega-hydroxy fatty acid ascaroside		Caenorhabditis elegans metabolite;
pheromone
ConditionIndicatedRelationship StrengthStudiesTrials
Acute Liver Injury, Drug-Induced0low10
Adenocarcinoma0low20
Adenocarcinoma, Basal Cell0low20
Adenocarcinoma, Granular Cell0low20
Adenocarcinoma, Oxyphilic0low20
Adenocarcinoma, Tubular0low20
Adenoma, Malignant0low20
Allergic Contact Dermatitis0low20
Benign Neoplasms0low40
Breast Cancer0low10
Breast Carcinoma0low10
Breast Neoplasms0low10
Breast Tumors0low10
Cadaver0low10
Cancer0low40
Cancer of Breast0low10
Cancer of Colon0low10
Cancer of Liver0low10
Cancer of Lung0low10
Cancer of Prostate0low10
Cancer of the Breast0low10
Cancer of the Colon0low10
Cancer of the Liver0low10
Cancer of the Lung0low10
Cancer of the Prostate0low10
Cancer, Hepatocellular0low10
Candida Infection0low10
Candidiasis0low10
Carcinoma, Cribriform0low20
Carcinoma, Granular Cell0low20
Carcinoma, Hepatocellular0low10
Carcinoma, Tubular0low20
Cheilitis0low20
Chemical and Drug Induced Liver Injury0low10
Chemically-Induced Liver Toxicity0low10
Colon Cancer0low10
Colon Neoplasms0low10
Colonic Cancer0low10
Colonic Neoplasms0low10
Congenital Zika Syndrome0low10
Congenital Zika Virus Infection0low10
Contact Dermatitis0low30
Corpse0low10
Dementia Praecox0low10
Dermatitis Venenata0low30
Dermatitis, Allergic Contact0low20
Dermatitis, Allergic Eczematous0low20
Dermatitis, Contact0low30
Dermatitis, Contact, Allergic0low20
Disease Models, Animal0low10
Drug-Induced Acute Liver Injury0low10
Drug-Induced Liver Disease0low10
Drug-Induced Liver Injury0low10
Eczema, Contact0low30
Extravascular Hemolysis0low30
Fever, Zika0low10
Fungal Diseases0low10
Fungal Infections0low10
Fungus Diseases0low10
Fungus Infections0low10
Haemolysis0low30
Helicobacter Infections0low10
Hemolysis0low30
Hepatic Cancer0low10
Hepatic Neoplasms0low10
Hepatitis, Drug-Induced0low10
Hepatitis, Toxic0low10
Hepatocellular Cancer0low10
Hepatocellular Carcinoma0low10
Hepatoma0low10
Human Mammary Carcinoma0low10
Hypersensitivity, Contact0low30
Idiopathic Parkinson Disease0low10
Idiopathic Parkinson's Disease0low10
Infections, Helicobacter0low10
Infections, Plasmodium0low10
Infections, Prosthesis-Related0low10
Infections, Staphylococcal0low10
Intravascular Hemolysis0low30
Lewy Body Parkinson Disease0low10
Lewy Body Parkinson's Disease0low10
Lip Diseases0low10
Liver Cancer0low10
Liver Cancer, Adult0low10
Liver Cell Carcinoma0low10
Liver Cell Carcinoma, Adult0low10
Liver Injury, Drug-Induced0low10
Liver Injury, Drug-Induced, Acute0low10
Liver Neoplasms0low10
Lung Cancer0low10
Lung Neoplasms0low10
Malaria0low10
Malignancy0low40
Malignant Melanoma0low10
Malignant Neoplasm of Breast0low10
Malignant Neoplasms0low40
Malignant Tumor of Breast0low10
Mammary Cancer0low10
Mammary Carcinoma, Human0low10
Mammary Neoplasm, Human0low10
Mammary Neoplasms, Human0low10
Marsh Fever0low10
Melanoma0low10
Middle Ear Inflammation0low10
Moniliasis0low10
Mycoses0low10
Neoplasia0low40
Neoplasm0low40
Neoplasms0low40
Neoplasms, Benign0low40
Neoplasms, Breast0low10
Neoplasms, Colonic0low10
Neoplasms, Hepatic0low10
Neoplasms, Liver0low10
Neoplasms, Lung0low10
Neoplasms, Prostate0low10
Neoplasms, Prostatic0low10
Neoplasms, Pulmonary0low10
Otitis Media0low10
Paludism0low10
Paralysis Agitans0low10
Parkinson Disease0low10
Parkinson Disease, Idiopathic0low10
Parkinson's Disease0low10
Parkinson's Disease, Idiopathic0low10
Parkinson's Disease, Lewy Body0low10
Periodontal Pocket0low10
Plasmodium Infections0low10
Pocket, Periodontal0low10
Primary Parkinsonism0low10
Prostate Cancer0low10
Prostate Neoplasms0low10
Prostatic Cancer0low10
Prostatic Neoplasms0low10
Prosthesis Related Infection0low10
Prosthesis-Related Infection0low10
Prosthesis-Related Infections0low10
Pulmonary Arterial Hypertension0low10
Pulmonary Cancer0low10
Pulmonary Neoplasms0low10
Recrudescence0low10
Recurrence0low10
Relapse0low10
Remittent Fever0low10
Sarcoma 1800low10
Sarcoma 180, Crocker0low10
Schizophrenia0low10
Schizophrenic Disorders0low10
Sensitivity and Specificity0low10
Sensitivity, Contact0low30
Staphylococcal Infections0low10
Staphylococcus aureus Infection0low10
Toxic Hepatitis0low10
Tumors0low40
Tumors, Breast0low10
Weight Gain0low10
Zika Fever0low10
Zika Virus Disease0low10
Zika Virus Infection0low10
ZikV Infection0low10

Research Highlights

Safety/Toxicity (3)

ArticleYear
Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Jun-15, Volume: 104		2017
The efficacy and safety of bufadienolides-loaded nanostructured lipid carriers.
International journal of pharmaceutics, Jun-30, Volume: 393, Issue: 1-2		2010
Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells.
International journal of pharmaceutics, Feb-04, Volume: 348, Issue: 1-2		2008
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (5)

ArticleYear
Solid Lipid Nanoparticles of Dronedarone Hydrochloride for Oral Delivery: Optimization, In Vivo Pharmacokinetics and Uptake Studies.
Pharmaceutical nanotechnology, Volume: 7, Issue: 5		2019
Formulation, Characterization, and Pharmacokinetic Studies of 6-Gingerol-Loaded Nanostructured Lipid Carriers.
AAPS PharmSciTech, Volume: 19, Issue: 8		2018
Investigations on pharmacokinetics and biodistribution of polymeric and solid lipid nanoparticulate systems of atypical antipsychotic drug: effect of material used and surface modification.
Drug development and industrial pharmacy, Volume: 43, Issue: 4		2017
Preparation, characterization, pharmacokinetics and tissue distribution of solid lipid nanoparticles loaded with tetrandrine.
AAPS PharmSciTech, Volume: 12, Issue: 3		2011
Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics.
International journal of pharmaceutics, Apr-20, Volume: 335, Issue: 1-2		2007
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (21)

ArticleYear
Preparation of astaxanthin micelles self-assembled by a mechanochemical method from hydroxypropyl β-cyclodextrin and glyceryl monostearate with enhanced antioxidant activity.
International journal of pharmaceutics, Aug-10, Volume: 605		2021
Development of tamoxifen-loaded surface-modified nanostructured lipid carrier using experimental design:
IET nanobiotechnology, Volume: 14, Issue: 4		2020
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, Volume: 96, Issue: 5		2019
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
The Journal of biological chemistry, 11-15, Volume: 294, Issue: 46		2019
Solid Lipid Nanoparticles of Dronedarone Hydrochloride for Oral Delivery: Optimization, In Vivo Pharmacokinetics and Uptake Studies.
Pharmaceutical nanotechnology, Volume: 7, Issue: 5		2019
Beta-carotene-Encapsulated Solid Lipid Nanoparticles (BC-SLNs) as Promising Vehicle for Cancer: an Investigative Assessment.
AAPS PharmSciTech, Feb-05, Volume: 20, Issue: 3		2019
Characterization, anti-oxidative effect of grape seed powder and in silico affinity profiling of polyphenolic and extra-phenolic compounds for calpain inhibition.
Journal of pharmaceutical and biomedical analysis, Feb-05, Volume: 164		2019
Sustained release biodegradable solid lipid microparticles: Formulation, evaluation and statistical optimization by response surface methodology.
Acta pharmaceutica (Zagreb, Croatia), Dec-20, Volume: 67, Issue: 4		2017
Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation.
Current drug delivery, Volume: 14, Issue: 7		2017
Role of Isradipine Loaded Solid Lipid Nanoparticles on the Pharmacodynamic Effect in Rats.
Drug research, Volume: 67, Issue: 3		2017
Nanostructured lipid carriers as a potential vehicle for Carvedilol delivery: Application of factorial design approach.
Artificial cells, nanomedicine, and biotechnology, Volume: 44, Issue: 1		2016
Design and characterization of Amoitone B-loaded nanostructured lipid carriers for controlled drug release.
Drug delivery, Volume: 20, Issue: 8		2013
Exploration of hydrophobic modification degree of chitosan-based nanocomplexes on the oral delivery of enoxaparin.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Nov-20, Volume: 50, Issue: 3-4		2013
Oral bioavailability and stability study of a self-emulsifying drug delivery system (SEDDS) of amphotericin B.
Current drug delivery, Volume: 10, Issue: 5		2013
A novel mathematical model considering change of diffusion coefficient for predicting dissolution behavior of acetaminophen from wax matrix dosage form.
International journal of pharmaceutics, May-30, Volume: 428, Issue: 1-2		2012
Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations.
Journal of pharmaceutical sciences, Volume: 100, Issue: 2		2011
In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: level A in vitro-in vivo correlation.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Volume: 75, Issue: 2		2010
Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles.
Journal of controlled release : official journal of the Controlled Release Society, Feb-10, Volume: 133, Issue: 3		2009
Effects of monoglycerides on rhodamine 123 accumulation, estradiol 17 beta-D-glucuronide bidirectional transport and MRP2 protein expression within Caco-2 cells.
Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, Volume: 11, Issue: 3		2008
Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics.
International journal of pharmaceutics, Apr-20, Volume: 335, Issue: 1-2		2007
Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability.
Journal of controlled release : official journal of the Controlled Release Society, Aug-10, Volume: 114, Issue: 1		2006
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (10)

ArticleYear
Preparation and characterization of lutein ester-loaded oleogels developed by monostearin and sunflower oil.
Journal of food biochemistry, Volume: 43, Issue: 11		2019
Effect of lipid and cellulose based matrix former on the release of highly soluble drug from extruded/spheronized, sintered and compacted pellets.
Lipids in health and disease, Jun-09, Volume: 17, Issue: 1		2018
Multiparticulate system combining taste masking and immediate release properties for the aversive compound praziquantel.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Nov-15, Volume: 109		2017
Lipids bearing extruded-spheronized pellets for extended release of poorly soluble antiemetic agent-Meclizine HCl.
Lipids in health and disease, Apr-12, Volume: 16, Issue: 1		2017
Fabrication, Characterization, In vitro Evaluation of Solid Lipid Nanoemulsion of Flunarizine dihydrochloride for Nasal Delivery.
Anti-inflammatory & anti-allergy agents in medicinal chemistry, Volume: 15, Issue: 3		2017
An empirical model for dissolution profile and its application to floating dosage forms.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Jun-02, Volume: 56		2014
A novel mathematical model considering change of diffusion coefficient for predicting dissolution behavior of acetaminophen from wax matrix dosage form.
International journal of pharmaceutics, May-30, Volume: 428, Issue: 1-2		2012
A theoretical approach to evaluate the release rate of acetaminophen from erosive wax matrix dosage forms.
International journal of pharmaceutics, Jul-29, Volume: 414, Issue: 1-2		2011
Curcuminoids-loaded lipid nanoparticles: novel approach towards malaria treatment.
Colloids and surfaces. B, Biointerfaces, Nov-01, Volume: 81, Issue: 1		2010
Influence of the composition of glycerides on the solid-state behaviour and the dissolution profiles of solid lipid extrudates.
International journal of pharmaceutics, Nov-03, Volume: 381, Issue: 2		2009
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]